Michael Burchmore

2.5k total citations · 1 hit paper
9 papers, 2.0k citations indexed

About

Michael Burchmore is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Michael Burchmore has authored 9 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 2 papers in Radiology, Nuclear Medicine and Imaging and 1 paper in Molecular Biology. Recurrent topics in Michael Burchmore's work include HER2/EGFR in Cancer Research (7 papers), Cancer Treatment and Pharmacology (6 papers) and Peptidase Inhibition and Analysis (4 papers). Michael Burchmore is often cited by papers focused on HER2/EGFR in Cancer Research (7 papers), Cancer Treatment and Pharmacology (6 papers) and Peptidase Inhibition and Analysis (4 papers). Michael Burchmore collaborates with scholars based in United States and Canada. Michael Burchmore's co-authors include Dennis J. Slamon, Maureen Murphy, Steven Shak, Louis Fehrenbacher, Lyndsay N. Harris, Debu Tripathy, Charles L. Vogel, William Novotny, Melody Cobleigh and Stanford J. Stewart and has published in prestigious journals such as Journal of Clinical Oncology, European Journal of Cancer and Oncology.

In The Last Decade

Michael Burchmore

9 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

2002 1.5k citations Charles L. Vogel, Melody Cobleigh et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Burchmore United States	9	1.6k	906	655	352	291	9	2.0k
Nancy T. Sklarin United States	17	1.6k 1.0×	784 0.9×	783 1.2×	418 1.2×	397 1.4×	36	2.3k
Maureen Murphy United States	5	2.3k 1.5×	1.2k 1.3×	697 1.1×	404 1.1×	491 1.7×	6	3.0k
Sharon A. Baughman United States	8	1.7k 1.1×	1.2k 1.3×	929 1.4×	326 0.9×	242 0.8×	10	2.3k
Kim Leitzel United States	20	1.3k 0.8×	743 0.8×	623 1.0×	330 0.9×	219 0.8×	35	1.6k
Carolina P. Schröder Netherlands	22	1.1k 0.7×	1.2k 1.4×	466 0.7×	384 1.1×	500 1.7×	56	2.1k
José Jiménez Spain	14	992 0.6×	407 0.4×	893 1.4×	268 0.8×	287 1.0×	39	1.6k
Stanford J. Stewart United States	9	2.5k 1.6×	1.5k 1.6×	872 1.3×	404 1.1×	534 1.8×	14	3.5k
Neil A. O’Brien United States	23	1.0k 0.7×	375 0.4×	821 1.3×	265 0.8×	455 1.6×	55	1.6k
C. Willemien Menke‐van der Houven van Oordt Netherlands	25	1.0k 0.7×	1.1k 1.2×	377 0.6×	327 0.9×	428 1.5×	99	2.1k
Thijs H. Oude Munnink Netherlands	17	896 0.6×	944 1.0×	467 0.7×	237 0.7×	436 1.5×	43	1.8k

Countries citing papers authored by Michael Burchmore

Since Specialization

Citations

This map shows the geographic impact of Michael Burchmore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Burchmore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Burchmore more than expected).

Fields of papers citing papers by Michael Burchmore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Burchmore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Burchmore. The network helps show where Michael Burchmore may publish in the future.

Co-authorship network of co-authors of Michael Burchmore

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Burchmore. A scholar is included among the top collaborators of Michael Burchmore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Burchmore. Michael Burchmore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Vogel, Charles L., Melody Cobleigh, Debu Tripathy, et al.. (2023). Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer. Journal of Clinical Oncology. 41(9). 1638–1645. 16 indexed citations

2.

Vogel, Charles L., Melody Cobleigh, Debu Tripathy, et al.. (2002). Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer. Journal of Clinical Oncology. 20(3). 719–726. 1508 indexed citations breakdown →

3.

Osoba, David, Dennis J. Slamon, Michael Burchmore, & Maureen Murphy. (2002). Effects on Quality of Life of Combined Trastuzumab and Chemotherapy in Women With Metastatic Breast Cancer. Journal of Clinical Oncology. 20(14). 3106–3113. 111 indexed citations

4.

Vogel, Charles L., Melody Cobleigh, Debu Tripathy, et al.. (2001). First-Line Herceptin<sup>®</sup> Monotherapy in Metastatic Breast Cancer. Oncology. 61(Suppl. 2). 37–42. 145 indexed citations

5.

Osoba, David, et al.. (2001). Health-related quality of life (HRQL) in women with HER2-positive metastatic breast cancer: effect of treatment with trastuzumab (Herceptin) plus chemotherapy versus chemotherapy alone. European Journal of Cancer. 37. S189–S189. 11 indexed citations

6.

Vogel, Charles L., Melody Cobleigh, Debu Tripathy, et al.. (2001). First-line, single-agent Herceptin® (trastuzumab) in metastatic breast cancer. European Journal of Cancer. 37. 25–29. 145 indexed citations

7.

Osoba, David & Michael Burchmore. (1999). Health-related quality of life in women with metastatic breast cancer treated with trastuzumab (Herceptin).. PubMed. 26(4 Suppl 12). 84–8. 39 indexed citations

8.

Baselga, José, et al.. (1999). Health-related quality of life (HRQL) in women with HER2-overexpressing metastatic breast cancer (MBC) in a phase III study of Herceptin (R) plus chemotherapy versus chemotherapy alone. European Journal of Cancer. 35. S318–S318. 8 indexed citations

9.

deAndrade, J. Robin, et al.. (1994). THE USE OF KETOROLAC IN THE MANAGEMENT OF POSTOPERATIVE PAIN. Orthopedics. 17(2). 157–166. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact